PTC-209 (hydrobromide)

PTC-209 hydrobromide is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 hydrobromide irreversibly impairs colorectal cancer-initiating cells (CICs) . PTC-209 hydrobromide shows potent anti-myeloma activity and impairs the tumor microenvironment[1][2].

Product Specifications

CAS Number

[1217022-63-3]

UNSPSC

12352005

Target

Autophagy; BMI1

Type

Reference compound

Related Pathways

Autophagy; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PTC-209-hydrobromide.html

Purity

99.02

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1=C(C2=CSC(NC3=C(Br)C=C(OC)C=C3Br)=N2)N4C=CC=NC4=N1.Br

Molecular Formula

C17H14Br3N5OS

Molecular Weight

576.10

References & Citations

[1]Kreso A, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014 Jan;20 (1) :29-36.|[2]Christian Mayr, et al. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells. Oncotarget. 2016 Jan 5; 7 (1) : 745-758.|[3]Shahi MH, et al. BMI1 is expressed in canine osteosarcoma and contributes to cell growth and chemotherapy resistance. PLoS One. 2015 Jun 25;10 (6) :e0131006.